Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GeoVax Labs ( (GOVX) ) has provided an announcement.
On July 1, 2025, GeoVax Labs, Inc. announced a public offering of approximately 9.2 million common units, each priced at $0.65, raising gross proceeds of about $6 million. The offering, which closed on July 2, 2025, included shares of common stock and warrants to purchase additional shares, with the proceeds intended for working capital and general corporate purposes. The company has agreed to certain restrictions on issuing additional shares or convertible securities for a period following the offering, impacting its financial strategy and market operations.
The most recent analyst rating on (GOVX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines against infectious diseases and therapies for solid tumor cancers. The company is advancing its lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine, through Phase 2 trials, and is also developing a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, for advanced head and neck cancers. Additionally, GeoVax is working on a vaccine targeting Mpox and smallpox, with plans to move directly to Phase 3 clinical evaluation.
Average Trading Volume: 1,027,566
Technical Sentiment Signal: Sell
Current Market Cap: $7.72M
See more data about GOVX stock on TipRanks’ Stock Analysis page.